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Huntington’s disease (HD) is an inherited, fatal disorder in which the primary pathology
is neurodegeneration, particularly cortical thinning and atrophy of the caudate nucleus
and putamen. The disease is caused by the expansion of a CAG repeat region in exon
1 of the HTT gene, resulting in the expression of an expanded, mutant huntingtin
protein (mHTT). Individuals with just one HTT allele containing more than 40 CAG
repeats are invariably affected by the disease, while individuals with fewer than 36
CAG repeats on both alleles do not manifest the disease.1,2 The age of symptom onset
is inversely related to the number of CAG repeats and influenced by genetic modifier
loci on chromosomes 8 and 15.3,4 No disease-modifying treatment yet exists.
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Abstract: Therapies targeting mutant huntingtin DNA, mRNA, and protein have a chance at
becoming the first disease-modifying treatments for Huntington’s disease, a fatal inherited neurodegenerative disorder for which only symptom management treatments are available today. This
review focuses on evidence addressing several key questions pertinent to huntingtin-lowering,
ranging from the functions of wild-type huntingtin (wtHTT) that may be disrupted by huntingtinlowering treatments through the various ways huntingtin can be lowered, the tolerability of wtHTTlowering in mice and primates, what has been found in the Ionis Pharmaceutical safety trial of a
huntingtin-lowering therapy, and to the question of how much mutant huntingtin may need to be
lowered for a therapy to be clinically effective. We conclude that adverse consequences of lowering
wtHTT in animals appear to be brain region-specific, and/or dependent upon the animal’s stage
of development and the amount by which huntingtin is lowered. Therefore, safe approaches to
huntingtin-lowering in patients may be to lower huntingtin only moderately, or lower huntingtin
only in the most affected brain regions, or lower huntingtin allele-selectively, or all of the above.
Many additional questions about huntingtin-lowering remain open, and will only be answered
by upcoming clinical trials, such as whether the delivery approaches currently planned will be
adequate to get the treatment to the necessary brain regions, and whether non-allele-selective
huntingtin-lowering will be safe in the long run. Meantime, there is a role for preclinical research
to address key knowledge gaps, including the effects of non-allele-selective huntingtin-lowering
on protein trafficking and viability at the cellular level, the tolerability of wtHTT-lowering in the
corticostriatal connections of the primate brain, and the effects of this lowering on the functioning
of neurotransmitter systems and the transport of neurotrophic factors to the striatum.
Keywords: Huntington’s disease, huntingtin-lowering, gene therapy, cortex, striatum, CAG
repeat disorder
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Studies in cells and animal models of HD have found
mHTT to have a myriad of disruptive effects, including transcriptional dysregulation, impairment of protein degradation
systems, mitochondrial dysfunction, and altered synaptic
plasticity.5 Some treatments targeting downstream effects
of mHTT have shown efficacy in animal models of HD,
but none have shown efficacy in the human disease today.
Consequently, the best approach to treatment appears to be
the targeting of huntingtin itself, seeking to eliminate or at
least lower the expression of mHTT. In principle, this can be
accomplished by various technologies, including intrabodies
targeting the huntingtin protein, antisense oligonucleotides
(ASOs) or RNAi agents targeting the mRNA transcripts,
zinc-finger repressors to prevent mRNA transcription, or gene
editing of HTT DNA itself. With the exception of the latter
approach, these techniques will reduce but not completely
eliminate the production of mHTT. Therefore, the term
“huntingtin-lowering” is the preferred term for this class of
potential therapies. As discussed later in this review, the first
trial of a huntingtin-lowering agent in patients has recently
been completed by Ionis Pharmaceuticals, showing via an
assay for mHTT in the cerebrospinal fluid (CSF) that lowering of HTT was achieved and there were no adverse events
attributable to the agent.
Although many questions will only be answered by clinical trials, it is of interest to review what has been learned
about the effects of huntingtin-lowering since the discovery
of the HTT gene in 1993. This review focuses on key questions regarding the rationale, safety, possible efficacy, and
possible side-effects of huntingtin-lowering as a treatment
for HD, surveying the empirical evidence that bears on these
questions.

Is lowering the expression of mHTT
protein the right objective?
HD is due to toxic properties of mHTT rather than just loss
of wild-type huntingtin (wtHTT) function. While wtHTT is
necessary in early life (knockout of the mouse homologue
of huntingtin is embryonically lethal6–8), individuals lacking
wtHTT because both their alleles contain an expanded CAG
repeat region can be healthy for decades.
Could provision of “extra” wtHTT to a patient be a therapeutic option? In neuronal and non-neuronal cells transfected
with mHTT, co-transfection of wtHTT significantly reduces
cell death.9 In mice with a yeast artificial chromosome (YAC)
for mutant human huntingtin, a pro-apoptotic effect of mHTT
on cells in the testes is completely inhibited in mice that are
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hemizygous or homozygous for wild-type murine huntingtin
(Htt).10 YAC18 mice overexpressing a normal repeat length
transgene (18 CAGs) are protected against neurodegeneration induced by striatal injection of quinolinic acid.11
However, other evidence indicates that a treatment based on
supplementing wtHTT expression would be insufficient. A
genetic cross of YAC128 mice (128 CAGs) and YAC18 mice
produces offspring that overexpress wtHTT in the context
of mHTT. Though these offspring have mild improvement
in striatal cross-sectional area compared to YAC128 mice,
they show no significant improvement in motor coordination, striatal volume, striatal neuronal numbers, or striatal
DARPP-32 expression.12
Is the mHTT protein the only pathogen in HD? Some loss
of wtHTT function and possible effects of protein products
produced by repeat-associated non-ATG (RAN) translation
of the expanded mRNA have been hypothesized to also play
a role in the disease. Products of RAN translation from mHTT
mRNA have been found in HD human brains, and the toxicity of expanded HTT exon1 mRNA in human neuroblastoma
cells can be blocked by anti-CAG small RNA.13 Intrastriatal
injection of a locked nucleic acid consisting of CTG repeats
(complementary to CAGs) induces rapid motor improvement
in the R6/2 mouse model of HD without lowering either
mHTT or wild-type protein levels in these mice.14 Therefore,
while lowering of mHTT is essential, huntingtin-lowering
therapies utilizing agents that target HTT at the mRNA level
(ASOs and RNAi agents) might be more advantageous than
those that act only on the protein product (eg, anti-huntingtin
intrabodies). However, for these agents, consideration must
be given to the potential for the agent to target other genes
and transcripts besides HTT, producing “off-target” effects.
Although recommended by the Oligonucleotide Safety Working Group,15 in silico approaches to predicting the off-target
effects and toxicity of ASOs based on their sequence16 are
not perfect. Therefore, ASO developers utilize a combination
of in silico screening, in vivo screens for liver toxicity, and
transcriptome-wide evaluations of gene suppression to identify
lead candidates.17 Developers of RNAi agents expressed from
DNA delivered by a viral vector rely heavily on in vitro and
in vivo screening of candidate sequences, because chemical
modification is not available as a way to improve any inadequate specificity of a chosen candidate.
Different types of huntingtin-lowering therapies also
differ in their advantages and disadvantages with regards to
route of delivery, longevity of effect, reversibility, control of
dosing, etc. See Wild and Tabrizi18 for a review.
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Can HTT-lowering be accomplished allele
specifically if necessary?
Ever since it was determined that huntingtin protein is
required for embryogenesis6–8 and early development,19
consideration has been given to the possibility of lowering
expression of the mutant huntingtin allele while preserving
expression of wtHTT in heterozygous individuals. Many
approaches have proven feasible in cell and animal models
of HD. Because a single nucleotide mismatch between an
siRNA and a complementary mRNA can substantially reduce
its RNAi activity, an siRNA targeting a single-nucleotide
polymorphism (SNP) site in HTT in a heterozygous cell can
reduce expression of the allele with the matching nucleotide
of the SNP while leaving expression of the other allele much
less affected. van Bilsen et al20 designed siRNA targeting
SNPs in the HD gene and identified siRNA that are alleleselective in reducing HTT in fibroblasts from heterozygous
HD patients. They also developed a simple method for
identifying which SNP variant is on the same allele as the
expanded CAG repeat allele using SNP variant-specific
primers for the reverse transcription step of an RT-PCR assay.
Subsequently, Zhang et al21 demonstrated allele specificity
using an siRNA targeting a polymorphic deletion (Δ2642)
linked to the CAG repeat allele in HD fibroblasts. Carroll et
al22 identified numerous ASOs that are potent and selective
for their respective SNP target in vitro and in vivo when
injected into the brains of transgenic mouse models of HD.
A disadvantage of leveraging SNPs to achieve allele
specificity in huntingtin-lowering is that there is currently no
known single SNP that can be used as the basis for an allelespecific therapy in all HD patients. Genotyping followed by
combinatorial analysis of the frequency and co-occurrence
of 26 SNP sites on the alleles of 327 unrelated European
Caucasian HD patients showed that a repertoire of seven
allele-specific siRNAs would be needed for 85.6% of those
patients to be treatable by at least one of the siRNA.23 A similar analysis sequencing 22 SNP sites in 225 HD samples led
to the estimate that 5 siRNAs targeting 3 SNPs could provide
therapy for 75% of the US and European HD populations.24
Although encouraging, these findings are still daunting with
regards to the cost of developing and achieving regulatory
approval for multiple agents.
Could an allele-specific agent be found that would apply
to all patients? Initial attempts to use ASOs to target the
expanded CAG repeat itself achieved only modest allele
selectivity.25 However, advances in chemically modified oligonucleotides and the use of multiple mismatches within an
agent’s sequence has led to the identification of ss-RNAs that
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can inhibit the translation of mHTT with high potency and
selectivity.26 The ss-RNAs can distinguish between 44 CAG
repeats and 15 CAG repeats on the alleles of patient-derived
cells (GM04719); however, many patients have a difference
between the repeat lengths of their alleles that is smaller
than this (44 CAGs is the median number found in patient
samples).2 Also, these agents might have off-target effects,
lowering expression of other genes that contain CAG repeats.
Another option for targeting the CAG repeat region is
the use of zinc-finger proteins (ZFPs).27 Using a repressor
element targeted to the CAG repeat region of the HD gene
with ZFPs that bind CAGs, Zhang et al28 achieved about
90% repression of mHTT expression with minimal effect
on normal CAG length alleles in fibroblasts derived from
HD patients. In another approach, Garriga-Canut et al29
screened long ZFP chains designed to bind both the CAG
and complementary GTC strand of long HD repeat regions
more strongly than shorter repeat regions. In a cell line from
a knockin model of HD (STHdhQ7/Q111), these ZFPs fused with
a Kox-1 repressor element reduced mutant huntingtin mRNA
by almost 80% and mutant protein expression by 95% while
reducing neither protein nor RNA produced from the wildtype allele (Q7). Both investigators found their ZFPs function
in vivo to improve the phenotype of the R6/2 mouse model
of HD.28,29 However, further development of these entities
toward clinical trials has not yet been reported.
Finally, another way to lower huntingtin allele specifically
may be to use CRISPR/Cas9 editing to delete DNA from the
mutant allele. Allele-specific gene editing can occur if the
single-stranded guide RNA used with Cas9 targets a SNP
site whereby one of the SNP variants either eliminates a
protospacer-adjacent motif (PAM) sequence (on the allele
to be preserved) or creates a PAM sequence (on the allele to
be edited). Monteys et al30 found that appropriately designed
sgRNA applied in pairs can result in allele-specific deletion
of genomic DNA spanning the 5′UTR and exon-1 of HTT in
heterozygous patient-derived fibroblasts in vitro and reduce
human mHTT expression in a BACHD mouse model of HD
to 40% in vivo. Similarly, Shin et al31 used sgRNA to selectively excise 44 kilobases of DNA spanning the promoter
region, transcription start site, and first three exons of HTT.
However, both approaches have the disadvantage that the
allele specificity depends upon SNPs in the HD gene, so no
single therapeutic agent would be applicable to all patients.
Of greater concern is the recent finding that gene editing
based on the dsDNA breaks produced by Streptococcus
pyrogenes Cas9 (SpCas9) can result in a wide variety of
unintended editing events, including large deletions that
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are non-contiguous with the targeted cut site.32 This safety
issue might be avoided using variants of Cas9 (nickases) that
produce single-stranded cuts in the DNA rather than dsDNA
breaks. Using such nickases, Dabrowska et al33 demonstrated
that the CAG repeat region can be precisely excised from
the HTT gene by targeting two sites, one at the 5′ end of the
CAG repeat and the other about 40 bases downstream of the
3′ end of the repeat. However, the excision is independent on
CAG repeat length, and thus is not allele specific. Substantial
additional research will be needed to develop a CRISPR/Cas9
agent that is allele specific and safe for in vivo human use.
Of note, one allele-specific approach to lowering huntingtin using oligonucleotides targeting SNP sites has advanced
to clinical trials. Patients are being recruited for two trials
(NCT03225833 and NCT03225846, Wave Life Sciences,
Ltd.) each using an oligonucleotide targeting one of the more
prevalent SNPs in the HD gene. However, other companies
investing in HD therapy development have opted for nonallele-specific approaches.

What functions of wtHTT may be
disrupted by non-allele-specific
huntingtin-lowering?
Concerns that lowering wtHTT in patients may have undesirable consequences have arisen from studies identifying many
functions of the normal protein. These have roles not only in
development but also in regulation of intracellular trafficking processes, formation of cortical and striatal excitatory
synapses, and in transcriptional regulation (for a review, see
Jimenez-Sanchez et al5). In vitro, wtHTT protects striatalderived cells from mitochondrial toxins.34 Both in vivo and
in vitro, wtHTT is phosphorylated in response to DNA damage, suggesting a role in the DNA damage response signal.35
Proteomic analyses have identified hundreds of proteins
that interact with wtHTT,36 supporting a view of HTT as a
scaffolding protein involved in numerous protein–protein
interactions.
wtHTT is also involved in many types of trafficking in
cells, including bidirectional transport of vesicles in neurons,37 trafficking between Golgi and extracellular space,38
transport via endocytic and secretory pathways,39 and secretory vesicle fusion at the plasma membrane40 where loss of
wtHTT results in ~50% decrease in the number of vesicle
fusion events per unit time. Investigations of wtHTT interaction with dynein and dydactin41 have led to the proposal of
models whereby wtHTT plays a global role in vesicle and
organelle transport throughout the cytoskeletal network.42

6

Powered by TCPDF (www.tcpdf.org)

submit your manuscript | www.dovepress.com

Dovepress

Dovepress

The wide variety and apparent centrality of the functions
of wtHTT (see Liu and Zeitlin43 for a detailed review) have
led to the question of whether HTT could be indispensable
in the adult brain. If so, excessive non-allele-specific lowering of huntingtin may not be safe. What evidence exists to
inform this issue?

What evidence is there concerning the
safety of lowering wtHTT?

wtHTT-lowering may not be safe in the developing
brain
In a study of mice with one null copy of Hdh and one copy
altered to express Htt at a greatly reduced level (~15% of
endogenous levels), the mice were small from birth and
had movement abnormalities and variable increases in
cerebroventricular volume.44 Studies using Cre-mediated
conditional knockout of Hdh in mice have shown that
knockout of Hdh at various stages of embryonic and postnatal development results in deficiencies in cortical neuron
migration,45 abnormalities in cortical and striatal synaptic
development,46 and behavioral and neurological abnormalities that are not reversed by later restoration of ~50% Htt
expression (at P21).47

In vitro evidence related to the safety of wtHTTlowering
Much evidence giving rise to safety concerns about huntingtin-lowering comes from in vitro studies, particularly
those identifying a role wtHTT plays in the production and
transport of brain-derived neurotrophic factor (BDNF) and
BDNF mRNA.48 Wild type but not mHTT promotes cortical
BDNF gene transcription by inhibiting the BDNF silencing
activity of the neuron restrictive silencer element.49 Huntingtin interacts indirectly with the REST/NRSF-interacting LIM
domain protein through dynactin;50 in the case of mHTT, this
interaction is weaker. This is consistent with the finding that
BDNF mRNA and protein levels are reduced in HD.51 Further reduction due to non-allele-specific huntingtin-lowering
could jeopardize the survival of medium spiny neurons of
the striatum, which are dependent upon cortically derived
BDNF52and particularly vulnerable in HD. In neuroblastoma
cells, reduction of HTT by siRNAs reduces the velocity of
vesicle transport and increases the time vesicles spend without moving.53 Her et al54 studied primary cortical neurons
from Hdh floxed mice and found that complete knockout of
Htt from these cortical neurons did not affect their viability,
but reduced both anterograde and retrograde transport of
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particles in their axons. Interestingly, they also found that
axonal transport of BDNF was not affected in primary cortical neurons transfected with mHTT.54
Caviston et al41 have found that reduction of HTT protein by 83% in HeLa cells results in the Golgi becoming
stretched out or vesicular in these cells, disrupting protein
transport particularly of proteins destined for the extracellular compartment. This consequence may not arise in
huntingtin-lowering treatments using agents that do not
achieve this extent of HTT reduction, but could arise in
treatments involving gene editing. The clinical relevance of
this effect may depend upon whether, in the long-term, there
are compensatory adaptations in cells that would mitigate
this disruption of the Golgi.

In vivo evidence regarding the safety of wtHTTlowering in adults: mouse studies
At least three studies have investigated the consequences
of complete knockout of Htt in adult mice at various
ages, with conflicting conclusions. Wang et al55 crossed
conditional Hdh knockout mice56 with mice that express a
tamoxifen-inducible Cre, producing inducible Htt knockout
mice. Depletion of Htt in mice by tamoxifen injection at
2 months of age resulted in 95% mortality due to acute
pancreatitis. In contrast, 95% of mice in which Htt was
depleted at 8 months of age survived long term (studied
for 10–11 more months) with no significant differences in
rotarod performance, body weight, or the expression of
various proteins (LC3I/II, P62, caspase-3, NfκB, FAT10)
in the brain and peripheral tissues. They also crossed floxed
Hdh mice with transgenic mice expressing Nestin-CreER,
producing mice in which tamoxifen injection eliminated
Htt expression in neurons and not peripheral tissues. These
mice, injected with tamoxifen at 2, 4, or 8 months of age,
showed no differences in brain volume or histology, and
no differences over 7–8 months time in post-injection body
weight, rotarod performance, or gripping ability compared
to heterozygous Hdh knockout controls. These results suggest that lowering and even elimination of wtHTT may be
safe if depletion of wtHTT occurs only in the brain or only
in older individuals.
However, a study by Dietrich et al57 produced distinctly
different results. In their study, CAG-CreER mice were
first crossed with heterozygous knockout mice (Hdh+/-) and
offspring were subsequently crossed with Hdhflox/flox mice,
producing CreER;Hdhflox/- mice, termed cKO mice. These
cKO mice express ~50% of the level of endogenous Htt
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compared to wild-type mice from conception. Administration of tamoxifen to cKO mice results in nearly complete
elimination of Htt expression (evaluated by Western blot),
reduction in Htt mRNA in total brain extracts to <15% of
wild-type levels (evaluated by RT-PCR), and reduction
of Htt expression in the cortex and striatum to <20% of
wild-type levels (evaluated by electrochemiluminescence
assay). Regardless of when tamoxifen was administered
to these mice (at age 3, 6, or 9 months), the mice developed progressive gait abnormalities, resting tremors, and
substantially reduced rotarod performance within 1–3
months after huntingtin-lowering. They also had a shortened life span compared to cKO mice not administered
tamoxifen. No pancreatitis was reported in this study in
mice administered tamoxifen at 3 months of age, although
other adverse effects of huntingtin-lowering were observed
in peripheral tissues, including thickening of the cornea
observed in about one-third of tamoxifen-treated cKO mice
and testicular atrophy seen in tamoxifen-treated males.
Histologically, the most pronounced findings were early
development of reactive gliosis in the cerebellum and
thalamus within 3 months of huntingtin-lowering and later
development of calcification in the thalamus (seen as early
as 13 months of age and confined to the thalamus). Ferric
iron levels were significantly reduced throughout the brains
of tamoxifen-treated cKO mice, including in the striatum
and cortical neuronal cells. Conversely, although reactive
gliosis was seen in the striatum 9 months after huntingtinlowering, no overt loss of cells was observed in the cortex
even 14 months after huntingtin-lowering, and no change
in DARPP-32 expression or overt cell loss was seen in the
striatum 12 months after huntingtin-lowering. Overall,
these observations suggest that huntingtin-lowering may
be tolerated in the striatum and cortex more than in other
regions of the brain.
A third study of huntingtin-lowering in the adult mouse was
performed by Pla et al58 These investigators crossed CaMKCreER mice (in which tamoxifen activation of Cre recombinase
occurs only in mature cortical and hippocampal neurons) with
Hdhflox/flox mice to obtain offspring in which Hdh was inactivated
in these neurons by administering tamoxifen to the mice at 2
months of age. Six months later, investigation of hippocampal
neurogenesis in the dentate gyrus of the mice showed impaired
maturation and differentiation of newborn neurons (assessed by
dendritic arborization) and reduced survival of newborn neurons. These mice showed no obvious motor deficits in rotarod
tests, but spent significantly less time than controls in the center
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of an open field and less time in open arms of an elevated plus
maze, indicative of an anxious phenotype. Western blotting
of protein extracts from the hippocampi of the mice indicated
that although BDNF levels were no different from controls,
Erk and Akt (kinases involved in intracellular signaling upon
BDNF binding to cell surface receptors) were less extensively
phosphorylated in the tamoxifen-treated mice than in controls.
This suggests that BDNF signaling was impaired due to a
reduction in BDNF transport or release. The investigators suggest that some of the anxiety disorders prevalent among HD
patients may be caused by loss of normal HTT function in the
hippocampus and cortex, particularly with regards to BDNF
transport, due to a dominant negative effect of mHTT (although
Her and Goldstein54 did not find a dominant negative effect of
mHTT in BDNF transport in primary cortical neurons).
It is difficult to reconcile the results of these three studies. Wang et al did not report testing their mice for behavior
indicative of an anxious phenotype; Dietrich et al did not
find pancreatitis or dramatically early mortality in their
conditional cKO mice treated with tamoxifen at 3 months
of age in contrast to the findings of Wang et al in mice
treated at 2 months of age; Wang et al did not observe the
progressive behavioral deficits, thalamic calcifications, or
other adverse effects of huntingtin elimination or lowering
reported by Dietrich et al. Barring procedural, environmental, or genetic background differences, the best explanation
might be that, as noted by Dietrich et al, the effects of Htt
elimination may be more deleterious in a mouse that has
had only 50% of normal endogenous levels of Htt in its life
prior to Htt elimination (in their study) than in a mouse with
normal levels of Htt prior to tamoxifen administration (in
the Wang et al study).

In vivo evidence that wtHTT-lowering in adulthood is
tolerated: non-human primate studies
We and others have studied the effects of lowering wild-type
Htt in non-human primates whose neurophysiology, basal
ganglia anatomy, and behavioral repertoire more closely
resembles that of humans. McBride et al59 stereotactically
injected 10–12 µL of 1E12 vg/mL AAV2/1 encoding a
huntingtin-lowering miRNA (miHDS1) into each of three
sites in the putamen in one hemisphere of adult male rhesus
macaques (n=4). Animals were assessed pre- and postoperatively on general behavior and motor skill assays and
euthanized 6 weeks post-AAV administration for molecular
and histological analyses. AAV-miHDS1-injected recipients
showed a significant 45% reduction in wild-type Htt mRNA
expression in the putamen compared to animals that received
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a control miRNA. Compared to controls, AAV-miHDS1injected animals showed no motor skill deficits, no significant
decrease in the mRNA for DARPP-32 (a marker for medium
spiny neurons), and no loss of NeuN-positive neurons in the
putamen.
We conducted a much longer study in rhesus macaques60
using bilateral injections of a larger quantity and higher titer
of AAV. Adult females were injected bilaterally with 2E12
vg/mL of either AAV2-HD5 (a huntingtin-lowering shRNA,
n=4) or AAV2-CTRL5 (a scrambled shRNA, n=4) into
three sites per hemisphere, one in the caudate (30 µL) and
two in the putamen (60 µL each). Six months later, shRNA
transcripts were detected in the targeted brain regions, and
HD5 vector recipients showed a 30% reduction in wtHtt
mRNA and an average wtHtt protein reduction of 45%
(range 32%–67% reduction) relative to controls. Home-cage
activity levels and motor performance on an automated
hand-retrieval task were not adversely affected by either
AAV2-HD5 or CTRL5 delivery. Motor memory was also
preserved as all animals recalled and performed the retrieval
task without intervening practice between the monthly test
sessions. There was no significant effect on immunostaining
for DARPP-32, and no discernible neuronal loss or abnormal astrocytosis noted in any of the animals upon blinded
microscopic evaluation by a board-certified pathologist. Our
study therefore showed that 32%–67% reduction of wtHtt is
safe and well-tolerated in the primate caudate and putamen
for at least 6 months.
In addition to using viral vectors, our group has also
evaluated the use of programmable pumps and intraparenchymal catheters to chronically deliver huntingtin-lowering
siRNA directly into the rhesus striatum.61,62 Intraparenchymal catheters were implanted unilaterally into the right putamen of adult, female rhesus monkeys and connected to an
abdominally implanted pump from which siRNA (or PBS,
in controls) was delivered. Continuous infusion of siRNA
for 28 days was well-tolerated and resulted in up to 75%
lowering of Htt mRNA in individual brain tissue samples,
and ~45% suppression of Htt mRNA on average throughout
most of the rhesus striatum. Decreased neuronal levels of
Htt protein were indicated by a pronounced attenuation of
immunostaining intensity in the putamen of siRNA recipients. No behavioral changes were observed. Microscopic
evaluations conducted on Fluoro-Jade B-stained brain sections did not reveal any continuing neuronal necrosis in any
of the control or siRNA-treated animals. Normal patterns
of Nissl-stained neurons were retained in corresponding
brain regions.
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Together, these results support the feasibility and safety
of wtHtt reduction in the primate brain. In addition, Ambrose
et al63 have noted a case in humans of a phenotypically normal
female in whom the HD locus was bisected by a balanced
translocation, indicating that heterozygous disruption of HTT
from conception onward was fully tolerated in this individual.
It should be noted, however, that it is possible that the tolerability of wtHTT reduction may be different in patients in
the context of mHTT expression, and that the time required
for a reduction in wtHtt to have ill effects in primates may
be longer than the primate studies reported so far.

What has been learned about huntingtin-lowering in
large animal models of HD?
Because of the inherent limitations of rodent models of HD,
including but not limited to basal ganglia anatomy, brain size,
and lifespan, there has been interest in developing transgenic
models of HD in sheep, minipigs, and non-human primates.
These larger animals have a longer pubertal age and gestation time, so breeding can be a slow and expensive process,
especially in primates. Data from only five male and three
female transgenic HD monkeys have been reported to date.64
The three females had a severe motor phenotype necessitating
euthanasia within a month of birth.65 A longitudinal study of
four males showed deterioration of motor and cognitive skills
with age and enlargement of lateral ventricles as seen in the
human disease.66 However, the small numbers of these animals has precluded extensive studies of huntingtin-lowering
in these transgenic primates.
Conversely, a limitation for the use of transgenic sheep
and minipigs so far is that they have been slow in developing a clear disease-related phenotype.67–69 For example, only
sparse cortical mHTT aggregates were found in 18-month-old
transgenic sheep along with nuclear inclusions in these sheep
at 36 months of age.70 At the age of 24 months, transgenic
minipigs have modest neuropathological changes, including
moderate microglial activation in the caudate and mHTT
fragments (but not aggregates) in the cytoplasm of striatal
and cortical cells, but remain asymptomatic.71 A recently
developed CRISPR/Cas9 knockin pig model may more
closely recapitulate HD features including gait abnormalities, enlarged lateral ventricles, and degeneration of striatal
medium spiny neurons.72
To date, few studies of huntingtin-lowering in these larger
transgenic models of HD have been reported. Pfister et al73
stereotactically injected the striatum of 8- to 14-month-old
transgenic sheep expressing full-length human HTT with
AAV9 encoding an artificial miRNA targeting the transgene.
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The treatment reduced human mHTT mRNA and protein by
50%–80% in the striatum at 1 and 6 months post-injection,
but not endogenous levels of sheep Htt protein. There was no
significant loss of striatal neurons at 6 months after treatment,
and Iba1-positive microglia levels were comparable to controls suggesting that safe and sustained silencing of human
mHTT protein can be achieved in a large animal’s brain by
direct delivery of an AAV carrying an artificial miRNA.
Similarly, bilateral administration of AAV5-miHTT in 20to 39-month-old transgenic minipigs significantly reduced
human mHTT mRNA and protein in the putamen (by 47.5%
and 53.0%, respectively), caudate nucleus (by 44.2% and
50.5%, respectively), and thalamus (by 72.8% and 53.5%,
respectively) 3 months following a single injection into both
the putamen and thalamus.74 The AAV5-miHTT treatment
did not significantly increase microglial expression or alter
DARPP-32 staining of medium spiny neurons. These studies
support the translation of AAV-delivered huntingtin-lowering
therapies to the clinic, but neither one was informative with
regards to the effect of the treatment on any disease phenotype of the animal. Also, since endogenous huntingtin was
not targeted by these therapeutic agents, additional studies
will be needed to address the tolerability of total huntingtinlowering in these larger transgenic models of HD.
A summary of animal studies regarding the tolerability of
the lowering of wtHTT protein by genetic means vs administration of a huntingtin-targeting agent, at different ages, and
by various amounts, is provided in Table 1.
The apparent tolerability of wtHTT-lowering in adult
animals, particularly primates, has led many organizations
to develop therapies for clinical use to focus on total huntingtin-lowering with non-allele-specific agents. Compared
to allele-specific approaches requiring multiple agents and
associated diagnostic kits for selecting the appropriate agent
for a given patient, a non-allele-specific approach may cost
less to develop and be easier to deploy.
Non-allele-specific therapy development efforts include
those by Ionis Pharmaceuticals in collaboration with Hoffman-La Roche to develop a huntingtin-lowering therapy
using ASOs, as well as efforts by uniQure, Inc., and by
Voyager Therapeutics in collaboration with Genzyme to
develop AAV-delivered RNAi agents. The Ionis Pharmaceuticals’ first clinical trial of a non-allele-specific huntingtinlowering agent has been completed. Despite the potential
safety concerns that could be raised based on preclinical
studies of the function of wtHTT and the effects of nonallele-specific lowering in animals, this trial was successful.
What was learned?
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Table 1 Tolerability studies of huntingtin-lowering in animals
Investigators/
reference

Species/
model

Mode of
reduction

Amount of wtHtt
lowering

Age at time of
wtHtt lowering

Was wtHtt lowering
well-tolerated?

Auerbach et al44
Arteaga-Bracho
et al47
Wang et al55

Mouse
Mouse

Genetic
Genetic (via Cre)

>85% knockout
Knockout

No
No

Mouse

Genetic (via Cre)

Dietrich et al57

Mouse

Genetic (via Cre)

Pla et al58

Mouse

Genetic (via Cre)

McBride et al59

Male rhesus

miRNA

Adult

Yes (for at least 6 weeks)

Grondin et al60

Female
rhesus
Female
rhesus
Sheep
Minipig
BACHD

shRNA

Adult

Yes (for at least 6 months)

Adult

Yes (for at least 28 days)

miRNA
miRNA
MoHuASO

Knockout
Knockout
Neuronal knockout
Neuronal knockout
Neuronal knockout
50% reduction then
knockout at:
or knockout at:
or knockout at:
Knockout in cortical and
hippocampal neurons
45% wtHtt reduction
(striatum)
45% wtHtt reduction
(striatum)
45% wtHtt reduction
(striatum)
No wtHtt reduction
No wtHtt reduction
83% wt mRNA reduction

Conception
During development
(< P21)
2 months age
8 months age
2 months age
4 months age
8 months age
From conception
3 months age
6 months age
9 months age
2 months age

Adult
Adult
2 months age

Not applicable
Not applicable
Yes (for at least 16 weeks)

BACHD

MoHuASO

25% wtHtt reduction

2 months age

Wild-type
mouse
Rhesus

MoHuASO

75% wtHtt reduction

2 months age

Yes (for at least 10
months)
Yes (for at least 4 months)

MkHuASO

Adult

Not reported

YAC128

ASO

53% mRNA reduction
(frontal cortex)
55% wtHtt reduction
(striatum)

2 months age

Yes (for at least 3 months)

Stiles et al61
Pfister et al73
Evers et al74
Kordasiewicz
et al81

Stanek et al82

Abbreviations: wt, wild type; ASO, antisense oligonucleotide.

What has the first trial of a non-allelespecific HTT-lowering treatment shown
in patients?
The Phase I/IIa trial of IONIS-HTTRX (NCT02519036),
completed in November 2017, was a randomized, placebocontrolled, dose-escalation trial of the safety and tolerability
of IONIS-HTTRX delivered by intrathecal injections via
lumbar puncture to patients with early HD.75 Five patient
cohorts were enrolled, with treated patients receiving four
monthly doses of 10, 30, 60, 90, or 120 mg of ASO per
injection, respectively. Patients were followed for 4 months
after their last injection. The treatment was found to be
safe and well-tolerated at all doses tested, with no serious
adverse events in patients receiving the ASOs. Importantly,
a dose-dependent reduction in mHTT in the patient’s CSF
was observed in CSF samples taken just prior to the drug
10
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siRNA

No
Yes
Yes
Yes
Yes
Yes
No
No
No
No
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administration at each month, and again in a follow-up
lumbar puncture. The extent of wtHTT-lowering was not
determined, because so far there is no assay available for
measuring total HTT protein in human CSF. In the highest
dose cohort, mHTT was lowered by an average of just under
40% relative to the patient’s baseline level. In a majority of
the patients receiving IONIS-HTTRX, the amount of mHTT
in the CSF was continuing to decline at the time of the last
treatment, suggesting that further monthly treatments could
lead to further reduction in mHTT.
However, there are limitations to the conclusions that can
be drawn from the trial. As a trial primarily concerned with
safety, it involved a small number of patients and a short duration (4 months) of therapy administration. Strictly speaking,
the main conclusions afforded by the trial are that the treatment was safe for the duration of the study and follow-up, and
Degenerative Neurological and Neuromuscular Disease 2019:9
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the treatment produces a reduction of mHTT in the CSF. However, as a double-blind, placebo-controlled trial in patients,
the data from the trial merit considerable weight among the
body of evidence about huntingtin-lowering available so far.
Potential challenges for this therapy going forward are the
long-term tolerability of the monthly intrathecal deliveries
(over half of the patients experienced pain and/or post-lumbar
puncture syndrome due to the procedure), and patient-topatient variability in the effect of the treatment delivery with
regards to mHTT-lowering. Although the mean lowering of
mHTT in the CSF of the patients in the highest dose cohort
was ~40% reduction from baseline, the range was extensive,
including a paradoxical ~20% increase in mHTT over baseline
in one patient. Nevertheless, an average reduction of 40% is
encouraging, and Roche is currently planning for a larger and
longer pivotal trial to determine the efficacy and continued
safety of IONIS-HTTRX (RG6042) in HD patients. All participants who took part in the Phase I/IIa study are continuing
to receive RG6042 as part of an “open-label extension” study
run by Ionis. This study assesses the safety and tolerability of
longer term dosing of RG6042. A randomized, double-blind,
Phase III trial to evaluate the efficacy and safety of RG6042
treatment given once per month or once every 2 months (bimonthly) over a period of 25 months (~2 years) is expected
to start enrolling patients in 2019.76
Ionis Pharmaceutical investigators and their partner,
Roche, are hypothesizing that a 40% reduction of protein in
the CSF is indicative of sufficient huntingtin-lowering in the
brain for clinical efficacy, as indicated by their proceeding to
invest in further trials aimed at efficacy. What is known from
animal models regarding the amount of mutant huntingtinlowering needed for efficacy?

By how much must mutant huntingtin
be lowered for a treatment to be
efficacious?
Numerous studies in rodent models of HD support the
efficacy of reducing mutant huntingtin mRNA and protein
levels in the brain for improving the disease phenotype,
whether using ASOs, siRNAs, shRNAs, miRNAs, or other
approaches. Partial reversal of disease progression and
delayed motor dysfunction was achieved in the severely
affected R6/1 transgenic mice by intrastriatal AAV5-mediated delivery of anti-Htt shRNA which lowered levels of
mHTT mRNA in the striatum by 78% and protein levels by
28%.77 Also, using AAV to deliver RNAi constructs to the
striatum, Boudreau et al78 showed that a 75% reduction of
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human mHTT and endogenous wild-type mouse Htt mRNA
levels was well-tolerated and prevented motor and neuropathological deficits in HDN171-82Q mice. Harper et al79
found that a more modest 51%–55% reduction in mHTT
mRNA in these HDN171-82Q mice was also sufficient for
phenotypic benefit, resulting in significant improvements
in gait deficits and rotarod performance. Along the same
lines, lentiviral delivery of inhibitory RNAs in a rat model
of HD that conferred just a 35% knockdown of huntingtin
gene expression of both mutant and wild-type alleles was
shown to be safe and provided both neuroanatomical and
behavioral benefits up to to 9 months after injection. 80
Using ASOs, Kordasiewicz et al81 report that reduction of
the expression of human mutant exon1 mRNA in the R6/2
mouse brain by 43% (±5%) was sufficient to prevent further
brain weight loss and significantly extend the lifespan of
these severely affected mice. They also reported that reduction in mHTT mRNA and protein levels in 6-month-old
YAC128 mice by 58% and 56% (ie, to 42% and 44% of
controls, respectively) restored their motor deficits to the
performance level of nontransgenic controls.81 Similarly,
Stanek et al82 found that reduction of both wild-type and
mutant huntingtin by ~40% in YAC128 mice resulted in
significant improvements in behavioral deficits, with no
notable overt neurotoxicity.
Unfortunately, because the various rodent models differ
in the nature of their mutant allele (number of CAGs, full
length or exon1 only, transgenic or knockin, etc), the number
of wtHTT alleles in their genotype, the level of expression of mHTT, and the severity of their phenotype, any
numerical extrapolation from these findings to the human
case is fraught with uncertainty even ignoring the species
difference between rodents and humans. For example, the
YAC128 mouse expresses its full-length 128 CAG-repeat
mHTT transgene at about 75% of endogenous mouse Htt
levels and manifests a disease phenotype,83 suggesting that
a 25% reduction in mHTT mRNA might not be sufficient as
a therapy. However, a lowering of mHTT by an intervention
may have different effects than the lowering due to a genetic
difference. On the other hand, even in a mouse model with
a severe phenotype (R6/2), reduction of mRNA expression
by 43% extended the animal’s lifespan. Therefore, there is
reason to be hopeful that the level of huntingtin-lowering
attainable by the ASOs, RNAi agents, and other approaches
progressing toward or in clinical trials will be sufficient
for therapeutic benefit, if the delivery of the agent to key
regions of the brain is adequate.
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Timing of huntingtin-lowering: how early
to start treatment?
Because HD is a progressive disease and individuals needing
treatment can be positively identified, it would seem desirable to start treatment as early in life as can be safely done.
However, some animal data suggest a need for caution with
regards to huntingtin-lowering treatments. For example,
a knockout of wtHTT in mice at 2 months of age (early
adulthood) produced acute pancreatitis.55 This may not pose
an issue for treatments in which wtHTT is lowered but not
eliminated, particularly for treatments delivered directly to
the central nervous system (CNS) with minimal “spill over”
and persistence systemically. Other studies in mice have
found that wtHtt is important for brain development,19,84 and
if wtHtt levels have been low during a developmental period,
restoration of wtHtt levels at a later age does not compensate
for the ill effects of an earlier deficiency.47 These findings
suggest that except in the case of juvenile HD (in which the
benefit may outweigh the risks), perhaps treatment should not
be initiated in people before they are in their early twenties. In
most cases, this precaution would still allow treatment to be
initiated many years before predicted clinical symptom onset.

Timing of huntingtin-lowering: how long
is long enough?
Because HD is a chronic and progressive neurodegenerative disease, it is unrealistic to expect that a short course of
huntingtin-lowering treatment will be curative – a successful
huntingtin-lowering treatment will be a life-long endeavor.
However, preclinical studies of huntingtin-lowering using
siRNA or ASOs support the conclusion that the administration of the treatment need not be continuous. The lowering
of HTT mRNA in primate brain has been found to persist for
weeks beyond the cessation of delivery of “naked” siRNA
into the tissue, even though the siRNA itself was not specially
synthesized or encapsulated to prevent its degradation.62
More importantly, Kordasiewicz et al81 showed that transient
administration of ASOs in HD transgenic mice was able to
degrade HTT mRNA and elicit phenotypic improvements that
persisted beyond the period of not only ASO administration
but also mRNA lowering. This has led to the interpretation
that cells can benefit from a “huntingtin holiday”, whereby
transient lowering of huntingtin expression enables compensatory mechanisms (yet to be fully delineated) to “catch
up” so cells can better handle the re-expressed huntingtin.85
This observation has supported the use of periodic rather
than continuous administration of ASOs in the trials of
IONIS-HTTRX. In the case of huntingtin-lowering agents
12
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that can be delivered using viral vectors (shRNA, miRNA,
intrabodies), continuous and perhaps lifelong delivery of the
treatment will be a function of the persistence of expression
of the delivered transgene. Finally, despite the other hurdles
faced by DNA editing approaches (eg, CRISPR-based gene
editing), the treatment is expected to be permanent, at least
in the cells transduced by the agent.

When both wtHTT and mHTT are
lowered, will the net result be beneficial?
Development of therapies involving non-allele-specific
huntingtin-lowering is based on the hypothesis that the net
result of lowering both wtHTT and mHTT in a patient will be
beneficial. If either an allele-specific or a non-allele-specific
agent results in lowering of mHTT protein to a greater extent
than it lowers wtHTT protein, there is reason to believe this
would be beneficial. Becanovic et al86 have studied samples
of patients with very early or very late age of disease onset
relative to the age of onset expected from their CAG repeat
numbers, and identified a SNP in the promoter region of HTT
that results in the lowering of expression of the huntingtin
protein on the cis-allele. If that allele is the mutant allele,
mHTT protein is lowered relative to wtHTT, and this lowering
is associated with a delayed age of onset. Conversely, if the
SNP variant is on the non-expanded allele, wtHTT protein
is lowered relative to mHTT protein, and the lowering is
associated with an earlier age of onset.
In a study identifying allele-selective ASOs in a humanized mouse model of HD, Southwell et al87 reported that a
non-allele-selective ASO resulted in reduced levels of HTT
with maintenance of the basal wild type to mutant protein
ratios in all areas of the CNS examined. Over the long term,
what if mHTT might accumulate disproportionately to
wtHTT due to differences in the efficiency of proteosome
degradation of the expanded repeat protein? A study of adultonset HD brain samples88 found that even though there was a
small but significantly lower expression of mutant huntingtin
mRNA compared to wild-type mRNA, wild type and mutant
protein levels did not differ significantly. In contrast, Liu et
al89 reported finding that mutant huntingtin mRNA exceeds
wild-type mRNA in post-mortem HD brains. An assay for
total HTT in CSF, if available for use in the next human trial
of IONIS-HTTRX, will answer the question about proportionate huntingtin-lowering.
The observations that wtHTT stimulates BDNF transcription49 and modulates anxiety and depression-like behaviors in
mice,90 among other observations, suggest that loss of wtHTT
function could be part of the pathogenesis of the disease. If
Degenerative Neurological and Neuromuscular Disease 2019:9
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both mHTT and wtHTT are lowered by an amount sufficient
for efficacy, will the net result be beneficial? Studies showing
the tolerability of huntingtin-lowering by ~45% in wild-type
animals do not address this question, because this result is
not in the context of a co-expressed mutant protein. Studies
showing benefit of non-allele-specific huntingtin-lowering in
mouse models of HD (eg, Boudreau et al78) also do not address
this question to the extent that in these models the mutant
transgene is overexpressed, or expressed in the presence of two
copies of the wild-type murine Hdh. The humanized Hu97/18
mouse expresses full-length human and mutant huntingtin
at similar endogenous levels,91 but to our knowledge the net
effect of long-term non-allele-specific huntingtin-lowering on
the phenotype of this mouse has not been reported.) Induced
pluripotent cell lines (iPS cells) derived from HD patients
and stably transduced with shRNA non-allele specifically
lowering HTT have been generated and are viable, but the
benefit of huntingtin-lowering in these cells is unclear.92
Lowering HTT by 50%–60% in these cells has no beneficial
effect on the level of p53 protein nor the functioning of the
MAP kinase signaling pathway, two aspects of the abnormal
phenotype of these cells. Conversely, Trager et al93 found that
lowering HTT by ~50% restores normal cytokine function in
patient-derived monocytes. However, it remains unknown as
to whether non-allele-specific huntingtin-lowering by ~50%
will restore cells of the CNS to normalcy.

Summary and conclusion
This review supports several conclusions about huntingtinlowering. It is clear that it is possible to lower huntingtin
in vivo in rodents, sheep, pigs, and non-human primates
using agents that could be administered to humans, such
as shRNA, miRNA, ASOs, zinc fingers, and CRISPR/Cas9
gene editing agents. With some agents, it is possible to
lower mutant huntingtin in an allele-selective manner. The
lowering of mutant huntingtin by various means is efficacious at improving the abnormal phenotype in many rodent
models of HD. In rodents, genetic reduction of wtHTT by
50% or more adversely affects the developing brain, and
near elimination of wild-type huntingtin is detrimental
even if not initiated until adulthood. Lowering wild-type
huntingtin by ~45% in the adult non-human primate striatum is well-tolerated for at least 6 months. Four months of
periodic administration of a non-allele-specific ASO that
lowers the level of mutant huntingtin detected in the CSF is
safe and well-tolerated in patients, and longer term studies
of the tolerability of the same ASO in primates are report-
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edly underway. In mice, some adverse effects of wtHTTlowering (eg, thalamic calcification) take 9 months to a
year to emerge, indicating that long-term preclinical studies
of the safety of huntingtin-lowering are advisable, even as
human trials are proceeding. It is notable that the adverse
effects in mice are the result of huntingtin-lowering to the
point of near elimination, rather than the more moderate
lowering typically achieved with clinically relevant agents.
Collectively, the evidence indicates that the potential adverse
effects of wild-type huntingtin-lowering are age, amount,
and perhaps brain region-specific (to the extent that near
elimination of Htt in wild-type mice eventually resulted in
calcification, specifically in the thalamus).57 For now, what
can be concluded is that for safety, huntingtin-lowering in
the human disease should be either limited in the amount by
which huntingtin is lowered (eg, preserving about 50% of
wild-type expression), limited to the most affected regions of
the brain (ie, the striatum and cortex, and probably avoiding
in particular the thalamus), or allele-specific, or all of the
above. This statement is dissatisfying relative to the desire
for parsimony in the interpretation of evidence, but it is not
unrealistic given that the disease itself is age, region, and
dose (CAG repeat number) specific.
Other important questions about huntingtin-lowering
remain open. Non-allele-specific lowering of huntingtin in
patients has been found to be safe, but whether it will be
safe over the long term remains unknown. Also, it remains
to be seen whether IONIS-HTTRX given via a lumbar route
of administration penetrates not only the cortex but also the
caudate nucleus and putamen of patients sufficiently for
clinical efficacy. It is possible that huntingtin-lowering only
in the cortex could have some benefit – in rodents, selective expression of mHTT only in striatal neurons produces
cell-autonomous deficits in striatal electrophysiology, but
spares the animal locomotor deficits and striatal degeneration.94 However, HD is a multi-system disease.95 Huntingtinlowering in at least both the cortex and the striatum may be
necessary in the human disease. It remains to be seen whether
miRNA against huntingtin delivered by AAV5 to the striatum
(as planned by uniQure) will be transported retrogradely to
the cortex sufficiently to lower huntingtin in layer V cortical
neurons projecting to the striatum, and whether other serotypes of AAV can deliver miRNA against huntingtin across
the blood–brain barrier sufficiently for a systemic route of
delivery to be feasible for clinical use in patients. Answers
to most of these questions will only be provided by clinical
trials over the next several years.
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What gaps in our knowledge about huntingtin-lowering
should be pursued by preclinical research in the meantime? A
fundamental question is whether lowering wild-type huntingtin in layer V cortical neurons in particular (not just generally
in cortical tissue) and thus the corticostriatal connections to
the striatum will be tolerated in the primate brain. Studies in
BACHD mice96,97 have indicated that huntingtin-lowering in
both cortical neurons and the striatum is likely to be necessary
for optimal treatment efficacy. However, other studies have
shown that wtHTT functions to promote the production of
BDNF,49 and transport of BDNF to the striatum is slowed53
when wtHTT is lowered. So far, studies in non-human primates showing that lowering of wtHTT is well-tolerated have
not measured and demonstrated huntingtin-lowering specifically in layer V cortical neurons whose efferents form the
corticostriatal tract. Studies using treatment delivery methods
that achieve simultaneous lowering of huntingtin in both the
striatum and the cortical neurons projecting to it are needed
to establish whether reducing wtHTT by about 40%–50%
in the corticostriatal pathway has adverse effects on BDNF
levels or otherwise adversely effects the functioning of striatal neurons. If so, this would indicate that an allele-specific
approach will be necessary.
To our knowledge, the use of patient-derived embryonic
stem cells or iPS cells to address the question of whether
lowering of both wild-type and mutant huntingtin results in
a net benefit at the cellular level has not been fully exploited,
particularly in cells differentiated to a phenotype resembling
cortical neurons or medium spiny neurons of the striatum.
Also, so far, huntingtin-lowering studies in non-human primates have not been long enough or inclusive of the thalamus
enough to cover another knowledge gap – whether lowering
of wtHTT by a clinically relevant amount in the thalamus of
the primate brain will eventually result in thalamic calcification, as seen in mice.57
Although many open questions and hurdles remain, much
progress is being made toward a huntingtin-lowering therapy
for HD. Scientists, clinicians, patients, and their families
can look forward with interest to further developments in
this field.
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